ValuEngine cut shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) from a hold rating to a sell rating in a research note published on Monday.

Other equities analysts also recently issued research reports about the stock. Barclays PLC started coverage on shares of Sarepta Therapeutics in a research report on Wednesday, September 6th. They set an equal weight rating and a $46.00 price objective for the company. William Blair restated an outperform rating on shares of Sarepta Therapeutics in a research report on Thursday, July 27th. Morgan Stanley upgraded shares of Sarepta Therapeutics from an equal weight rating to an overweight rating and set a $60.00 price objective for the company in a research report on Monday. BidaskClub downgraded shares of Sarepta Therapeutics from a buy rating to a hold rating in a research report on Friday, August 4th. Finally, Robert W. Baird restated an outperform rating and set a $101.00 price objective on shares of Sarepta Therapeutics in a research report on Wednesday, September 6th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $62.79.

Shares of Sarepta Therapeutics (SRPT) traded up 0.04% during mid-day trading on Monday, reaching $49.80. 153,690 shares of the company’s stock traded hands. The firm’s market capitalization is $3.20 billion. Sarepta Therapeutics has a 12-month low of $26.26 and a 12-month high of $63.03. The stock has a 50-day moving average price of $42.84 and a 200 day moving average price of $36.08.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.46. The firm had revenue of $35.01 million for the quarter, compared to analyst estimates of $22.52 million. The company’s revenue was up 350000.0% on a year-over-year basis. During the same quarter last year, the firm earned ($1.19) EPS. Analysts anticipate that Sarepta Therapeutics will post ($1.22) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “ValuEngine Lowers Sarepta Therapeutics, Inc. (SRPT) to Sell” was first reported by Marea Informative and is the property of of Marea Informative. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at http://www.mareainformativa.com/valuengine-lowers-sarepta-therapeutics-inc-srpt-to-sell/117107/.

In other Sarepta Therapeutics news, CEO Douglas S. Ingram purchased 47,058 shares of the business’s stock in a transaction that occurred on Thursday, July 27th. The shares were purchased at an average price of $42.50 per share, for a total transaction of $1,999,965.00. Following the completion of the acquisition, the chief executive officer now owns 382,058 shares of the company’s stock, valued at approximately $16,237,465. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Alexander Cumbo sold 5,918 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total transaction of $242,638.00. Following the completion of the transaction, the senior vice president now owns 22,793 shares in the company, valued at approximately $934,513. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 78,056 shares of company stock worth $3,224,208. Insiders own 9.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of SRPT. BlackRock Inc. raised its holdings in Sarepta Therapeutics by 4,403.1% in the first quarter. BlackRock Inc. now owns 5,292,729 shares of the biotechnology company’s stock valued at $156,664,000 after buying an additional 5,175,193 shares during the period. Camber Capital Management LLC purchased a new position in Sarepta Therapeutics in the first quarter valued at approximately $39,960,000. State Street Corp raised its holdings in Sarepta Therapeutics by 21.2% in the first quarter. State Street Corp now owns 3,197,127 shares of the biotechnology company’s stock valued at $94,641,000 after buying an additional 559,342 shares during the period. Voya Investment Management LLC raised its holdings in Sarepta Therapeutics by 2,786.1% in the second quarter. Voya Investment Management LLC now owns 568,525 shares of the biotechnology company’s stock valued at $19,165,000 after buying an additional 548,826 shares during the period. Finally, HealthCor Management L.P. raised its holdings in Sarepta Therapeutics by 31.1% in the second quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock valued at $68,495,000 after buying an additional 481,890 shares during the period. Hedge funds and other institutional investors own 65.41% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.